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StarvationSkeletal muscle atrophy occurs when the rate of protein degradation exceeds that of protein synthesis in various
catabolic conditions, such as fasting, disuse, aging, and chronic diseases. Insulin-like growth factor-1 (IGF-1)
signaling stimulates muscle growth and suppresses muscle protein breakdown. In atrophied muscles, ubiquitin
ligase, Cbl-b, increases and stimulates the ubiquitination and degradation of IRS-1, an intermediate in IGF-1
signaling pathway, resulting in IGF-1 resistance. In this study, we evaluated the efﬁcacy of atelocollagen
(ATCOL)-transported anti-ubiquitination oligopeptide (Cblin: Cbl-b inhibitor) (consisting of tyrosine phosphor-
ylation domain of IRS-1) in starved C2C12 myotubes. The amount of IRS-1 protein was lower in starved versus
unstarved myotubes. The Cblin-ATCOL complex inhibited IRS-1 degradation in a concentration-dependent
manner. Myotubes incubated with Cblin-ATCOL complex showed signiﬁcant resistance to starvation-induced
atrophy (p b 0.01). Furthermore, the Cblin-ATCOL complex signiﬁcantly inhibited any decrease in Akt phosphor-
ylation (p b 0.01) and localization of FOXO3a to the nucleus in starvedmyotubes. These results suggest that Cblin
prevented starvation-induced C2C12myotube atrophy bymaintaining the IGF-1/Akt/FOXO signaling. Therefore,
attachment of anti-ubiquitination oligopeptide, Cblin, to ATCOL enhances its delivery tomyotubes and could be a
potentially effective strategy in the treatment of atrophic myopathies.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Skeletal muscle atrophy in the presence of catabolic state associat-
ed with fasting, disuse, aging, and chronic diseases is due to imbal-
ance between rates of protein degradation and synthesis [24].
Insulin-like growth factor-1 (IGF-1) signaling promotes muscle
growth and suppresses muscle protein breakdown through Akt-
dependent phosphorylation and cytosolic sequestration of FOXO tran-
scriptional factors in skeletal myocytes, which leads to inhibition of
FOXO-dependent gene expression [22,23,25]. In contrast, IGF-1
signaling is impaired in atrophied muscles, with resultant increase
in the transactivation of FOXO target genes, such as atrophy-related
genes (atrogenes) that encode atrogin-1 and MuRF-1, which are
RING-type ubiquitin ligases known to be critical mediators of atrophic
myopathies [1,8].s and Dentofacial Orthopedics,
ima Graduate School, 3-18-15,
33 7357; fax:+81 88 633 9139.Cbl-b is a RING-type ubiquitin ligase established as a negative
regulator of receptor tyrosine kinase signaling in a variety of cells
[9,12,27]. In atrophied muscles, Cbl-b increases and interacts prefer-
entially with IRS-1, an intermediate in the IGF-1 signaling pathway,
resulting in loss of IRS-1-activated FOXO-dependant induction of
atrogin-1 [17]. Furthermore, Cbl-b-deﬁcient mice are resistant to
unloading-induced atrophy [17]. These results suggest that inhibition
of Cbl-b-mediated IRS-1 ubiquitination could be a useful therapeutic
strategy for muscle atrophy. Based on these ﬁndings, we developed
an anti-ubiquitination oligopeptide (Cblin: Cbl-b inhibitor) that
inhibits the interaction between Cbl-b and IRS-1 [17]. The peptide mi-
metic of tyrosine608-phosphorylated IRS-1 inhibited Cbl-b-mediated
IRS-1 ubiquitination and induction of atrogin-1 [17]. However, pep-
tides are rapidly degraded by aminopeptidases in the body, making
it difﬁcult to produce long-term therapeutic effects. Therefore, the
development of safe and effective delivery system is critical for the
treatment of various muscle atrophies with anti-ubiquitination
oligopeptides.
Atelocollagen (ATCOL), a pepsin-treated type I collagen lacking
telopeptides at the N and C terminals that confer antigenicity, has
been developed as a carrier material [[]]. It is reported that ATCOL
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and efﬁciently transfected into cells, thereby allowing long-term
gene silencing. Thus, ATCOL-based delivery method could be a reli-
able approach to achieve the maximal function of siRNA [16]. Based
on its practical use as a siRNA delivery, we have developed an
ATCOL-based oligonucleotide system for the delivery of a
myostatin-targeting siRNA into skeletal muscles and recently report-
ed that local administration of siRNA attached to ATCOL resulted in
marked stimulation of muscle growth and recovery of muscle
function in mutant caveolin-3 transgenic mice [11]. ATCOL forms a
complex with substances through electrostatic interaction and the
resultant complex allows increased cellular uptake, resistance to
degradation and prolonged release effect [10]. Thus, it seems that
the ATCOL complex is potentially applicable for the efﬁcient delivery
of oligopeptides.
The purpose of this study was to evaluate the effect of ATCOL-
carried anti-ubiquitination oligopeptide, Cblin (the ATCOL-Cblin
complex) in starved C2C12 myotubes. The Cblin-ATCOL complex
inhibited degradation of IRS-1 and dephosphorylation of Akt and
Foxo3a in starved myotubes. Moreover, myotubes incubated with
the Cblin-ATCOL complex showed resistance to starvation-induced
atrophy. The results suggest that the Cblin-ATCOL complex can
prevent muscle atrophy by maintaining proper IGF-1/Akt/FOXO
signaling.2. Materials and methods
2.1. Cell culture
C2C12myoblastic cells were purchased fromDainippon Pharmaceu-
tical Co. (Osaka, Japan) and maintained and proliferated at 37 °C under
5% CO2–95% air in Dulbecco's modiﬁed Eagle's Medium (DMEM),
supplemented with 10% fetal calf serum, 100 U/ml penicillin, and
0.1 mg/ml streptomycin. At 100% conﬂuence, the cells were fused by
replacing the medium with DMEM containing 2% horse serum. The
cells were maintained in 2% house serum (differentiation medium)
before the experiments. In starvation studies, the medium of the differ-
entiated myotubes was replaced with serum-free medium for 24 h of
incubation (serum starvation).2.2. Preparation of the Cblin-ATCOL complex
The anti-ubiquitination oligopeptide (Cblin: Cbl-b inhibitor) is a
pentapeptide corresponding to amino acids 606 to 610 of rat IRS-1
(DGpYMP) [17], synthesized by Thermo Fisher Scientiﬁc (Dreieich,
Germany). C2C12 myotubes were transfected with Cblin using ATCOL
(AteloGene®, KOKEN, Tokyo, Japan), 3 h before starvation. Cblin was
used at a ﬁnal concentration of 75.6 μM with 5% ATCOL. The Cblin-
ATCOL complex taken up into C2C12 myotubes in the differentiation
medium was observed using Cblin with FITC to the N-terminal under
BIOREVO BZ-9000 ﬂuorescent microscope (Keyence, Osaka, Japan).
The complex was prepared by mixing ATCOL at various amounts of
100, 200, 400 μL with a ﬁxed amount of 100 μg of Cblin and themixture
was added to 2 ml differentiation medium. The uptake efﬁciency of
Cblin-ATCOL complex into C2C12 myotubes was maximal when
100 μL ATCOL was mixed with 100 μg Cblin (Fig. S1). Honma et al.
[10] indicated that ATCOL establishes a complex with various physical
morphologies depending on its amount and that excess ATCOL formed
a complexwith ﬁbrousmorphology leading to deterioration of transfec-
tion efﬁciency into cultured cells. Therefore, we used the above
proportion of Cblin and ATCOL in the present experiment. The
unphosphorylated Cblin (DGYMP) was used as a control-peptide,
which has no inhibitory effect on IRS-1 ubiquitination, as reported in
our previous study [17].2.3. Measurement of myotube diameter
Myotubes were photographed at ×20 magniﬁcation after 24 h of
serum starvation using BIOREVO BZ-9000 ﬂuorescent microscope
(Keyence). At least 100 diameters were measured per group using
BIOREVO BZ-9000 software (Keyence).
2.4. Immunoblotting analysis
Cells were prepared in 50 mM Tris–HCl buffer (pH 7.5) containing
150 mM NaCl, 1% Triton X-100, 5 mM EDTA, 10 μM epoxomicin,
10 mM NaF, 2 mM Na3VO4, and a cocktail of protease inhibitors
(Roche Diagnostics, Tokyo, Japan). The samples were homogenized
using a sonicator. The BCA Assay (Pierce, Rockford, IL) was used to
quantify proteins. Protein samples were combined with 4× sample
buffer (250 mM Tris–HCl, 8% SDS, 40% glycerol, 8% beta-
mercaptoethanol, 0.02% bromophenol blue) and separated onto poly-
acrylamide gel. The proteins were transferred to a polyvinylidene
diﬂuoride membrane and probed with the primary antibody accord-
ing to the instructions provided by the manufacturer; the antibodies
used were rabbit polyclonal anti-IRS-1 (Millipore, Bedford, MA),
mouse monoclonal anti-Cbl-b (Santa Cruz Biotechnology, Santa Cruz,
CA), mouse monoclonal anti-Akt (BD Bioscience, San Jose, CA), rabbit
polyclonal phosphor-Akt (Ser473) (Cell Signaling Technology, Dan-
vers, MA), rabbit monoclonal anti-FOXO3a (Cell Signaling Technolo-
gy), rabbit polyclonal anti-phospho- FOXO3a (Thr32) (Cell Signaling
Technology), mouse monoclonal skeletal fast-type MHC (Sigma, St.
Louis, MO), and mouse monoclonal anti-β-actin (Sigma). Secondary
antibodies were anti-rabbit (dilution, 1:5000) and anti-mouse (dilu-
tion, 1:5000) (Amersham Pharmacia Biotech, Piscataway, NJ). Mem-
branes were developed using Amersham™ ECL™ western blotting
detection reagents (GE Healthcare, Buckinghamshire, UK).
2.5. Immunoprecipitation analysis
Cells were prepared using 500 μg protein and adjusted to 300 μL
with 50 mM Tris–HCl buffer (pH 7.5) containing 150 mM NaCl, 1% Tri-
ton X-100, 5 mM EDTA, 10 μM epoxomicin, 10 mM NaF, 2 mM
Na3VO4, and a cocktail of protease inhibitors. They were incubated
with either 0.5 μL of primary antibody at 4 °C for 3 hwith rotation. Thirty
μL of Protein G Sepharose™ 4 fast ﬂow (GE Healthcare) were added to
each IP sample and rotated at 4 °C for 16 h. Samples were washed 6
times in wash buffer, after which samples were prepared for SDS–
PAGE as described above.
2.6. Immunoﬂuorescence analysis
Cells were ﬁxed in 4% paraformaldehyde and permeabilized with
0.1% Triton X-100 and then blocked for 1 h at room temperature.
Next, the cells were incubated with primary antibody: rabbit
polyclonal anti-FOXO3a/FKHRL1 (Millipore) and mouse monoclonal
skeletal fast-type MHC (Sigma) overnight at 4 °C, followed by incuba-
tion with the secondary antibody: Alexa Fluor 568 goat anti-rabbit
IgG and Alexa Fluor 488 goat anti-mouse IgG (Life Technologies,
Gaithersburg, MD) for 1 h at room temperature. Finally, the cells
were incubated with Hoechst 33342 for 10 minutes at room temper-
ature and examined under BIOREVO BZ-9000 ﬂuorescent microscope
(Keyence).
2.7. Real-time RT-PCR
Total RNA was extracted from whole cells according to standard
protocols [3]. Real-time RT-PCR with SYBRTM Green dye was
performed using an ABI 7300 real-time PCR system (Applied
Biosystems, Foster City, CA) as described previously [9]. The follow-
ing oligonucleotide primers were used for ampliﬁcation: 5′-GGCG
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for Atrogin-1 cDNA; 5′-ACGAGAAGAAGAGCGAGCTG-3′ and 5′-
CTTGGCACTTGAGAGAGGAAGG-3′ for MuRF-1 cDNA; and 5′-CCCT
CACGCCATCCTGCGTC-3′ and 5′-CGGCAGTGGCCATCTCCTGC-3′ for
β-actin cDNA.2.8. Statistical analysis
Results were expressed as mean ± standard deviations. Differences
between groups were analyzed by the Student's t-test or analysis of
variance (ANOVA) using SPSS 16 (SPSS Japan, Tokyo). If ANOVA wasFig. 1. Effects of serum starvation on C2C12 myotubes. (A) Immunoﬂuorescently-stained C2C1
MHC antibody (green) and DNA staining (Hoechst: blue). Scale bars, 100 μm. (B) Immunoblo
myotubes. Right: Results of quantitative analysis. Representative data of three experimentswith
with unstarved myotubes (Student's t-test).signiﬁcant, the Bonferroni/Dunn procedure was used as a post hoc test.
In all tests, a p value less than 0.05was considered statistically signiﬁcant.3. Results
3.1. Induction of Cbl-b and degradation of IRS-1 in serum-starvedmyotubes
Starvation is a well-established muscle atrophy model both in vitro
and in vivo [13,21,22,28]. First, we examined the effect of starvation
on C2C12myotubes. Incubation in serum-freemedium for 24 h reduced
the diameter of C2C12 myotubes immunoﬂuorescently stained with2 myotubes incubated with differentiation medium or serum-free medium for 24 h, using
ts demonstrating reduced MHC and IRS-1 and increased Cbl-b protein levels in starved
similar results. Values aremean±SDof three experiments. *p b 0.05, **p b 0.01; compared
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mined by immunoblotting analysis (Fig. 1B; p b 0.01). We also de-
termined Cbl-b and IRS-1 protein levels in serum-starvedFig. 2. Inhibition of IRS-1 degradation by the Cblin-ATCOL complex. (A) Immunoprecipitation s
showing IRS-1 protein levels in 24-h serum-starved C2C12myotubes treatedwith cycloheximid
analysis. Representative data of three experiments with similar results. Values are mean ± SDmyotubes. Serum starvation for 24 h decreased IRS-1 and increased
Cbl-b protein levels (Fig. 1B; p b 0.05). Unloading-induced muscle
atrophy, such as spaceﬂight, denervation, and tail suspension,howing ubiquitination of IRS-1 in 24-h serum-starved C2C12 myotubes. (B) Immunoblots
e (CHX, 100 μg/ml) 12h after induction of serum starvation.Bottom: Results of quantitative
of three experiments. *p b 0.05 (ANOVA), **p b 0.01; compared with all groups (ANOVA).
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dation of IRS-1 [17,18]. These results suggest that serum starvation
increases Cbl-b protein and induces myotube atrophy through Cbl-
b-mediated degradation of IRS-1.
3.2. Inhibition of starvation-mediated degradation of IRS-1 by Cblin-ATCOL
complex
In the next series of experiments, we evaluated the efﬁciency of
Cblin on inhibition of IRS-1 ubiquitination and degradation. Immu-
noprecipitates from 24-h serum-starved C2C12 myotubes incubated
with an anti-IRS1 antibody were subjected to immunoblotting for
ubiquitin. Serum starvation stimulated the ubiquitination of IRS-1
in C2C12 myotubes and that the Cblin-ATCOL complex preventedFig. 3. Inhibition of C2C12 myotube atrophy by the Cblin-ATCOL complex. (A) Representative
medium. (b) C2C12 myotubes cultured in the differentiation medium with the Cblin-ATCOL c
Cblin-ATCOL complex. (d) C2C12 myotubes incubated in serum-free medium for 24 h with th
with control-peptide (unphosphorylated Cblin)-ATCOL complex. (B) Quantiﬁcation of myotu
(ANOVA).the starvation-induced ubiquitination of IRS-1 (Fig. 2A). In order to
examine starvation-mediated degradation of IRS-1, myotubes were
treated with cycloheximide (CHX, 100 μg/ml) 12 h after induction
of serum starvation, to inhibit the synthesis of new proteins. The
cells were harvested 12 h after the addition of CHX. The level of
IRS-1 protein decreased but Cblin-ATCOL complex inhibited the
degradation of IRS-1 in a concentration-dependent manner (Fig. 2B;
p b 0.05). However, Cblin alone did not inhibit the degradation of IRS-
1 effectively, and control peptide (unphosphorylated Cblin) had no ef-
fect on inhibition of degradation of IRS-1 (Fig. 2). These results indicate
that Cblin inhibits the degradation of IRS-1 and ATCOL is an effective
carrier material of Cblin. Based on this result, we decided to use
100 μg Cblin (ﬁnal concentration: 75.6 μM) with 100 μL ATCOL in the
following experiments.ﬁelds of myotubes Scale bars, 100 μm. (a) C2C12 myotubes cultured in the differentiation
omplex. (c) C2C12 myotubes incubated in serum-free medium for 24 h in the absence of
e Cblin-ATCOL complex. (e) C2C12 myotubes incubated in serum-free medium for 24 h
be diameter under different experimental conditions. Values are mean ± SD. **p b 0.01
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complex
Twenty-four hours after serum starvation, the diameter of C2C12
myotubes was signiﬁcantly decreased, compared with unstarved
myotubes (Fig. 3A, B; p b 0.01). On the other hand, C2C12myotubes treat-
ed with Cblin-ATCOL complex resisted atrophy induced by serum starva-
tion (Fig. 3A, B). Interestingly, the diameter of C2C12 myotubes culturedFig. 4. Effects of Cblin on IGF-1 signaling pathway in starved C2C12 myotubes. (A) Immunob
myotubes. Representative data of three experiments with similar results. Right: Results of q
(B) Localization of FOXO3a in 24-h serum-starved C2C12myotubes. Immunoﬂuorescence of C2
(Hoechst) or FOXO3a antibody. Scale bars, 50 μm. Arrows: entry of FOXO3a to the nucleus in s
C2C12 myotubes. Representative data of three experiments with similar results. Values are mein the differentiation medium did not increase in the presence of the
Cblin-ATCOL complex (Fig. 3A, B). C2C12 myotubes treated with
control-peptide (unphosphorylated Cblin)-ATCOL complex did not
show resistance to serum-starvation-mediated atrophy. Considered
together, the above results suggest that resistance to myotube atrophy
was not due to poor nutrient supply by degraded peptide and ATCOL
and that phosphorylation of tyrosine of Cblin is necessary for its inhibitory
effects.lots showing levels of phosphorylation of Akt and FOXO3a in 24-h serum-starved C2C12
uantitative analysis. Values are mean ± SD of three experiments. **p b 0.01 (ANOVA).
C12myotubes in the presence or absence of the Cblin-ATCOL complex, using DNA staining
tarved myotubes. (C) Expression of Atrogin-1 and MuRF-1 mRNAs in 24-h serum-starved
an ± SD of three experiments. **p b 0.01 (ANOVA).
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Next, we examined the effect of starvation on the expression of IGF-
1 signaling molecules and the mechanism of resistance to myotube
atrophy by Cblin-ATCOL complex. Serum starvation for 24 h signiﬁcant-
ly decreased the ratio of phosphorylated Akt to total Akt,whereas Cblin-
ATCOL complex signiﬁcantly inhibited the decrease in Akt phosphoryla-
tion (p b 0.01; Fig. 4A). In addition, suppression of Akt activity resulted
in dephosphorylation of FOXO3a (Fig. 4A) and entry of FOXO3a into the
nucleus of starved myotubes (Fig. 4B). However, these ﬁndings were
not observed in C2C12 myotubes treated with Cblin-ATCOL complex.
Serum starvation stimulated the expression of atrophy-related genes
(Atrogin-1 and MuRF-1), and Cblin suppressed the upregulation of
both ubiquitin ligases (p b 0.01; Fig. 4C). Akt is a major downstream
effector of IGF-1 signaling and FOXO is a family of transcription factors
regulated negatively by Akt function [22]. These results suggest that
Cblin inhibits Cbl-b-mediated IRS-1 degradation and maintains proper
IGF-1/Akt/FOXO signaling.
4. Discussion
Our ﬁndings suggested that ATCOL-transportation of anti-
ubiquitination oligopeptide, Cblin, prevented atrophy of starved C2C12
myotubes through proper maintenance of IGF-1/Akt/FOXO signaling.
Two major signaling pathways are involved in the regulation of
skeletal muscle growth: the IGF-1/Akt/FOXO signaling (positive regula-
tor) and myostatin/Smad3 signaling (negative regulator) pathways
[24]. Mutation of myostatin, a member of the transforming growth
factor β (TGF-β) superfamily, leads to a hypertrophic phenotype in
mice [14]. Our group also reported previously that knockdown of
myostatin resulted in increased skeletal muscle mass in mutant
caveolin-3 transgenic mice [11]. However, the mechanism of myostatin
activation and its role and capacity to trigger muscle atrophy remain
unclear [24]. On the other hand, pioneering studies on the molecular
mechanisms of muscle atrophy focused on the role of the IGF-1/PI3K/
Akt signaling cascade [22,25]. Akt regulates the ubiquitin-proteasome
system and this action is mediated by FOXO transcriptional factors. Akt
phosphorylates FOXO, promoting the export of FOXO from the nucleus
to the cytoplasm. Reduced activity of the Akt pathway leads to low levels
of phosphorylated FOXO in the cytoplasm with marked increase in nu-
clear FOXO [2]. Both the translocation and activity of FOXO is required
for upregulation of atrogin-1 and MuRF-1, which are ubiquitin ligases
and criticalmediators of atrophicmyopathies [25].Moreover, the ubiqui-
tin ligase, Cbl-b, plays amajor role in the downregulation of IGF-1 signal-
ing in skeletal muscle atrophy [17]. Previous studies from our group
demonstrated upregulation of Cbl-b in rat muscles exposed to 16-day
spaceﬂight [18]. Cbl-b ubiquitinated and induced speciﬁc degradation
of IRS-1, resulting in the inactivation of Akt and upregulation of
atrogin-1 through dephosohorylation of FOXO. Furthermore, Cbl-b-
deﬁcient mice were resistant to unloading-induced atrophy and loss of
muscle function [17]. Insulin/IGF-1 stimulates phosphorylation of
tyrosine608 of IRS-1 and Cbl-b preferentially binds to phosphorylated ty-
rosine residues of substrates [5,27]. The anti-ubiquitination oligopeptide
used in the present study was synthesized based on the above results,
and consisted of a tyrosine phosphorylation domain of IRS-1. The peptide
mimic of tyrosine608-phosphorylated IRS-1 inhibited Cbl-b-mediated
IRS-1 ubiquitination and induction of atrogin-1 [17]. In the present
study, myotubes treated with the Cblin-ATCOL complex showed resis-
tance to atrophy induced by starvation and the complex inhibited IRS-
1 degradation and Cbl-b-mediated dephosphorylation of Akt in starved
myotubes. Our results are consistent with the ﬁndings of a previous
study of competitive inhibition by Cblin of Cbl-b and IRS-1 interaction,
leading to a signiﬁcant inhibition of Cbl-b-mediated IRS-1 ubiquitination
and induction of atrogin-1 [17]. Moreover, the present results indicated
that the inhibitory mechanism of myotube atrophy by Cblin is mediated
through proper maintenance of IGF-1/Akt/FOXO signaling. In contrast,treatment of unstarvedmyotubeswith the Cblin-ATCOL complex neither
resulted inmorphological changes nor an increase in phosphorylation of
Akt and FOXO. These results show that Cblin protects by preventing the
induction of muscle atrophy-related genes, and that Cblin itself does not
promote muscle growth, like β2-adrenergic agonists or other anabolic
hormonal stimuli, leading to muscle hypertrophy [20].
The main obstacle to the development of peptide-based therapeutic
products is a suitable delivery method. ATCOL has low antigenicity
based on the elimination of telopeptides in the endogenous antigenic
region and has been used clinically for a wide range purposes, such as
hemostatic agent and wound dressing [4,15]. Recently, ATCOL has
been developed as carrier material for local and systemic delivery of
growth factor [6], plasmid DNA [19], and siRNA [16,26]. For cellular
uptake of nanoparticles, the surface charge is an important factor and
positively charged particles are better taken up than negatively charged
ones [7]. Cblin comprises negatively charged amino acid residues
(aspartate and phosphorylated tyrosine) that hinder its cellular uptake
because the cell surface exhibits substantial densities of negative
charges. However, ATCOL forms a complex with the negatively charged
Cblin through electrostatic interaction and the complex further
enhances the cellular uptake of Cblin. In the present study, the Cblin-
ATCOL complex inhibited degradation of IRS-1 in a concentration-
dependentmanner, while Cblin, even when used at high concentration,
was not effective in the absence of ATCOL. These results indicate that
ATCOL is a potentially useful and effective carrier for peptide delivery
as it increases the cellular uptake and prolongs the release of such
peptides, and enhances resistance to degradation.
In conclusion, we demonstrated in the present study the efﬁcacy of
the Cblin-ATCOL complex in preventing myotube atrophy by maintain-
ing the IGF-1/Akt/FoxO signaling. The results suggest that delivery of the
anti-ubiquitination oligopeptide, Cblin, through the use of ATCOL, is
potentially useful for effective treatment of atrophic myopathies.
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